



Poster programme

Poster session 1

Sunday 16 September 2018 - 17:00-18:30

Room: Aula

- [P1.01] **Licensing the first reduced, 6 µg dose seasonal influenza vaccine - A prospective, randomized-controlled multicenter trial**
Z. Vajo*¹, L. Kalabay¹, P. Vajo², G. Balaton¹, P. Torzsa¹, ¹*Semmelweis University, Hungary*, ²*University of Debrecen, Hungary*
- [P1.02] **HLA class II influence the antibody response to inactivated Japanese Encephalitis vaccine**
Y.F. Yao, H.J. Yang, L. Shi, J. Chen*, S.Y. Liu, C.Y. Li, M.B. Sun, L. Shi, *Chinese Academy of Medical Sciences, China*
- [P1.03] **National hepatitis B vaccination policies for healthcare workers in member-states of the European Union: an updated overview**
A.A. De Schryver*^{1,2}, T. Lambaerts², N. Lammertyn², ¹*University of Antwerpen, Belgium*, ²*IDWE Occupational Health Services, Belgium*
- [P1.04] ***Burkholderia* ΔtonB Δhcp1 live attenuated vaccines against acute respiratory Melioidosis and Glanders**
N. Khakhum*, P. Kilgore, J. Myers, P. Bharaj, J. Endsley, A. Torres, *University of Texas Medical Branch, USA*
- [P1.05] **Retrospective sero-survey to assess the measles susceptibility in Tyrol, Austria**
P.A.J. Kreidl*, D. Ammerer, W. Borena, *Medical University Innsbruck, Austria*
- [P1.06] **Development of a heat-stable MVA-based prime/boost vaccine against chronic hepatitis B**
K. Singethan¹, J. Sacherl*¹, K. Kemter², C. Jäger¹, A. Kosinska¹, A. Dislers³, S. Essbauer⁴, S. Hauck², M. Scholz², U. Protzer¹, ¹*Technische Universität München, Germany*, ²*Leukocare AG, Germany*, ³*Latvian Biomedical Research and Study Centre, Latvia*, ⁴*Bundeswehr Institute of Microbiology, Germany*
- [P1.07] **A chimeric yellow fever-Zika vaccine virus fully protects against lethal zika and yellow fever virus diseases in stringent murine challenge models**
D. Kum*, R. Boudewijns, J. Ma, N. Mishra, J. Neyts, K. Dallmeier, *KU Leuven, Belgium*
- [P1.08] **Evaluation of the therapeutic efficacy of the SNUMI-9 tuberculosis vaccine candidate originated from non-tuberculous mycobacteria**
H.J. Kim¹, B.J. Kim², S.K. Lee¹, S.H. Kim¹, B.J. Kim², Y.S. Lee¹, K.S. Lee*¹, ¹*Korea National Institute of Health, Republic of Korea*, ²*Seoul National University, Republic of Korea*
- [P1.09] **Impact of naturally occurring variation in the human Papillomavirus 58 capsid proteins on recognition by type-specific neutralizing antibodies**
A. Godi¹, M. Martinelli^{1,2}, M. Haque*¹, S. Li³, Q. Zhao³, N. Xia³, C.E. Cocuzza^{1,2}, S. Beddows¹, ¹*Public Health England, UK*, ²*University of Milano-Bicocca, Italy*, ³*Xiamen University, China*
- [P1.10] **Finnish healthcare workers' attitudes towards vaccines and motives for possible vaccine hesitancy**
L.C. Karlsson*¹, A. Soveri², J. Antfolk¹, P. Salo^{2,3}, M. Lindfelt¹, ¹*Åbo Akademi University, Finland*, ²*University of Turku, Finland*, ³*Finnish Institute of Occupational Health, Finland*
- [P1.11] **Very little evidence of vaccine hesitancy in Tshwane region 5 of Gauteng province, South Africa**
D.N. Montwedi, J.C. Meyer, V.V. Nkwinika, R.J. Burnett*, *Sefako Makgatho Health Sciences University, South Africa*
- [P1.12] **Vaccination sentiment on publically available South African social media platforms**
R.J. Burnett*, J.C. Meyer, M.M. Matsangaise, *Sefako Makgatho Health Sciences University, South Africa*
- [P1.13] **Vaccine refusal may have played a minor role in sub-optimal vaccination coverage in a hospital-based study in Gauteng province, South Africa**
R.J. Burnett*¹, G. Mmoleli¹, N.J. Ngcobo², C. Dochez³, L.M. Seheri¹, M.J. Mphahlele^{4,1}, ¹*Sefako Makgatho Health Sciences University, South Africa*, ²*Independent Consultant, South Africa*, ³*University of Antwerp, Belgium*, ⁴*South African Medical Research Council, South Africa*
- [P1.14] **Anti-vaccination conversations on online news forums, twitter, and other microblogs in South Africa**
M. Matsangaise¹, R. Burnett*^{1,2}, J. Meyer¹, ¹*Sefako Makgatho Health Sciences University, South Africa*, ²*South African Vaccination and Immunisation Centre, South Africa*
- [P1.15] **The impact of gut dysbiosis on coxsackievirus a16 infection in rhesus macaque**
H.Z. Li*, J.J. Wang, H. Li, X. Huang, Z.N. Yang, H.W. Zheng, L. Guo, M.M. Chu, L.D. Liu, *Peking Union Medical College, China*
- [P1.16] **Coxsackievirus A16 infection induces activation of the NLRP3 inflammasome**
X. Huang*¹, H.W. Zheng¹, H.Z. Li¹, L.D. Liu¹, ¹*Chinese Academy of Medical Sciences, China*, ²*Kunming Medical University, China*

- [P1.17] **Characterization of the genetic compatibility between a Rift Valley fever virus MP-12 vaccine strain and the Arumowot virus**
H.J. Hallam*, N. Lokugamage, T. Ikegami, *The University of Texas Medical Branch, USA*
- [P1.18] **Long-term immunoprotection of safe nanovaccine as a delivery system against scorpion envenoming: Immunogenicity and reactogenicity**
F.A. Nait Mohamed Mohamed, A. Nouri, F. Laraba-Djebari*, *USTHB, Algeria*
- [P1.19] **Inhibition of cell-mediated immunity in the presence of maternal antibodies during FMDV type O/S15KOR/2002 infection in pigs**
K. Roque*, H.M. Pyo, M.Y. Park, C.S. Kim, H.Y. Kim, J.S. Lim, J.W. Byun, S.H. Wee, *Animal and Plant Quarantine Agency, Republic of Korea*
- [P1.20] **Cytokine profiling in pigs inoculated with FMDV type O/S15KOR/2002**
K. Roque*, H.M. Pyo, M.Y. Park, C.S. Kim, H.Y. Kim, J.E. Park, J.S. Lim, H.J. Lyuk, S.H. Wee, J.W. Byun, *Animal and Plant Quarantine Agency, Republic of Korea*
- [P1.21] **Influence of booster administration of foot and mouth disease vaccines on the immune response in piglets with maternally-derived antibody**
C.S. Kim*, K. Roque, H.Y. Kim, J.E. Park, H.J. Lyuk, J.S. Lim, H.M. Pyo, J.W. Byun, S.H. Wee, M.Y. Park, *Animal and Plant Quarantine Agency, Republic of Korea*
- [P1.22] **Seroprotection on different levels of the health care system after vaccination with DTP-HepB-Hib in Laos**
L. Hefele^{1,2}, D. Kleine^{1,2}, S. Syphan³, D. Xayavong³, A. Homsana³, P. Chantavilay³, P. Nouanthong¹, K. Xaydalasouk¹, S. Billamay⁴, A. Xeuatvongsa⁵, A.P. Black¹, C.P. Muller^{1,2}, ¹*Institut Pasteur du Laos, People's Democratic Republic of Lao*, ²*Luxembourg Institute of Health, Luxembourg*, ³*Institut de la Francophonie pour la Médecine Tropicale, People's Democratic Republic of Lao*, ⁴*Children's Hospital, People's Democratic Republic of Lao*, ⁵*Expanded Programme on Immunisation, People's Democratic Republic of Lao*, ⁶*Laboratoire national de santé, Luxembourg*
- [P1.23] **Newly excysted juvenile of *Fasciola gigantica* shows potentials of vaccination against fasciolosis *gigantica* in mice**
P. Kueakhai*, N. Changklungmoa, *Burapha University, Thailand*
- [P1.24] **Vaccine potentials of excretory-secretory antigens of adult *Fasciola gigantica* against fasciolosis *gigantica* in mice**
N. Changklungmoa*, P. Kueakhai, *Burapha University, Thailand*
- [P1.25] **Evaluation of vaccine potential of recombinant vaccinia virus encoding H5 subtype hemagglutinin against H5N1 influenza viruses**
F. Yasui¹, K. Munekata¹, T. Fujiyuki², T. Kuraishi², T. Honda¹, Y. Sakoda³, M. Yoneda², H. Kida³, C. Kai², M. Kohara¹, ¹*Tokyo Metropolitan Institute of Medical Science, Japan*, ²*The University of Tokyo, Japan*, ³*Hokkaido University, Japan*
- [P1.26] **Essential role for serial immune responses in protection against influenza H5N1 in mice by an attenuated vaccinia virus vector expressing influenza virus H5 HA**
T. Honda¹, K. Munekata¹, F. Yasui¹, K. Yamaji¹, N. Sakaguchi², M. Kohara¹, ¹*Tokyo Metropolitan Institute of Medical Science, Japan*, ²*Osaka University, Japan*
- [P1.27] **Effective therapeutic vaccine for hepatitis C virus infection by heterologous antigen immuno-therapy**
Y. Shioyama¹, T. Ohtsuki², Y. Tokunaga², K. Yamaji², K. Tsukiyama-Kohara³, Y. Yasutomi¹, M. Kohara¹, ¹*National Institutes of Biomedical Innovation, Japan*, ²*Tokyo Metropolitan Institute of Medical Science, Japan*, ³*Kagoshima University, Japan*
- [P1.28] **Should South African healthcare workers be screened for immunity before hepatitis B vaccination? Evidence from Gauteng province**
L.L. Razwiedani¹, V.V. Nkwini¹, C. Dochez², A. De Schryver², R.J. Burnett¹, ¹*Sefako Makgatho Health Sciences University, South Africa*, ²*University of Antwerp, Belgium*
- [P1.29] **Study of effective oral vaccine to against *Miamiensis avidus* (Ciliophora:Scuticociliatida) of Olive flounder *Paralichthys olivaceus***
S.M. Shin*, S.J. Jung, *Chonnam National University, Republic of Korea*
- [P1.30] **Durability of neutralizing antibody response to vaccine and non-vaccine HPV Types 7 years following immunization with either cervarix® or gardasil® vaccine**
A. Godi*, M. Haque, K. Panwar, J. Southern, E. Miller, S. Beddows, *Public Health England, UK*
- [P1.31] **Understanding adult vaccine decision making and uptake: characteristics of policies and programs in upper-middle and high-income countries**
P. Vasudevan*, J. Gupta, G. Daggupati, N. Nawa, S.Y. Sim, D. Waters, N.M. Martin, L. Privor-Dumm, *Johns Hopkins Bloomberg School of Public Health, USA*
- [P1.32] **T cell mining *Pseudomonas aeruginosa* for novel vaccine targets**
H.A. Amr*, A.V. Dubois, R.J. Ingram, B.F. Gilmore, *Queen's University Belfast, UK*
- [P1.33] **Invasive pneumococcal disease in the Auckland, New Zealand: A case series**
G.E. Reynolds*, R. Simpson, N. Eichler, S. Thornley, F. Pobar, *Auckland Regional Public Health Service, New Zealand*
- [P1.34] **Changes of pneumococcal diseases incidences among elderly after National Immunization Program of pneumococcal polysaccharide vaccine to the elderly in Korea: an interrupted time-series analysis**
B.C. Chun*, S. Sohn, H-O. Noh, K. Hong, *Korea University Medical College, Republic of Korea*

- [P1.35] **Immune response induced by vaccines based on the protein, the gene (DNA) or prime-boost strategy against a multivalent chimeric antigen of *Brucella abortus***
A. Oñate*, R. Molina, M. Flores, L. Gómez, F. Alvarez, *Universidad de Concepción, Chile*
- [P1.36] **Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture**
C-C. Liu^{*1}, S-C. Wu², S-R. Wu³, H-Y. Lin¹, M-S. Guo¹, Y-C. Hu¹, Y-H. Chow^{1,4}, J-R. Chiang⁵, D-B. Shieh³, P. Chong^{1,4}, ¹National Institute of Infectious Diseases and Vaccinology, NHRI, Taiwan, ²National Tsing Hua University, Taiwan, ³National Cheng Kung University College of Medicine and Hospital, Taiwan, ⁴China Medical University, Taiwan, ⁵Vaccine Center, Centers for Disease Control, Taiwan
- [P1.37] **The assessment of post-vaccination monitoring for vaccine-based foot and mouth disease control in South Korea**
H.J. Lyuk^{1,2}, M.Y. Park^{*2}, J.W. Byun², H.M. Pyo², S.W. Wee², C.S. Kim², K. Roque², H.Y. Kim², J.E. Park², J.S. Lim², ¹Korea Institute of Science and Technology, Republic of Korea, ²Animal and Plant Quarantine Agency, Republic of Korea
- [P1.38] **Immune responses to vaccines against *Streptococcus pneumoniae* in mice selected for high and low acute inflammatory responses**
G.S. Oliveira, E.N. Miyaji, A. Soares-Schanoski, O.G. Ribeiro, M.L.S. Oliveira*, *Instituto Butantan, Brazil*
- [P1.39] **The European platform for animal experimentation on infectious diseases, to study animal and emerging diseases and the immune response to vaccination against pathogens**
M. Riou¹, I. Dimier-Poisson², J.F. Valarcher³, I. Schwart-Cornil⁴, E. Guitton¹, S. Abrioux¹ ¹PFIE, INRA, France, ²UMR-1282, INRA– Université de Tours, France, ³Swedish University of Agricultural Sciences, Sweden, ⁴VIM-INRA-Université Paris-Saclay, France
- [P1.40] **Chimeric recombinant monoclonal antibodies as a promising approach for passive immunization**
A.S. Oksanich, T.G. Samartseva*, I.V. Yakovleva, V.V. Sviridov, V.V. Zverev, *Mechnikov Research Institute for Vaccines and Sera, Russia*
- [P1.41] **Stability of dry powder vaccines**
R. Scherließ, *Christian-Albrechts-Universität Kiel, Germany*
- [P1.42] **Effective stabilization of viral vectors by liquid and lyophilized SPS® formulations - Adenovirus serotype 5 as a model**
E. Reinauer*, K. Kemter, J. Altrichter, M. Scholz, S. Hauck, *Leukocare AG, Germany*
- [P1.43] **Vaccination practice against measles for health care workers in Hong Kong**
H.L. Chan*, M.L. Wong, K.W. Au, S.K. Chuang, *Centre for Health Protection, Hong Kong*
- [P1.44] **Gene expression profiling identifies biomarkers related progression to tuberculosis**
E. Shin, J. Yun, Y-R. Lee, J.S. Yoo, G.T. Chung, H-S. Jeong*, *Korea Centers for Disease Control and Prevention, Republic of Korea*
- [P1.45] **Latest advancements in manufacturing to support global demand for affordable vaccines**
A. Luitjens, B. Pieters, M. Groothuizen*, *Batavia Biosciences, The Netherlands*

Poster session 2

Monday 17 September 2018 - 18:00-19:30

Room: Aula

- [P2.01] **Modification of neutralizing epitopes of Influenza Hemagglutinin for the development of broadly protective H9N2 vaccine**
P. Zhong Wee, W. Zhenzhang, R. Kumar, M. Prabakaran*, *National University of Singapore, Singapore*
- [P2.02] **Innate immune response to influenza A virus with truncated NS1 protein in mice**
K. Vasilyev*, A-P. Shurygina, M. Yukhneva, E. Romanovskaya-Romanko, M. Stukova, A. Egorov, *Research Institute of influenza, Russia*
- [P2.03] **Cross-reactive antibodies in elderly volunteers after 2017-18 trivalent influenza vaccine administration against B viruses belonging to B/Victoria and B/Yamagata lineages**
B. Camilloni^{*1}, A. Alunno¹, M.R. Castrucci², S. Puzelli², A.M. Iorio¹, ¹University of Perugia, Italy, ²Istituto Superiore di Sanità, Italy
- [P2.05] **A serological survey of H3N2 canine influenza A virus in dogs in 2016-2017, Korea**
I.O. Ouh*, S.Y. Park, I.S. Cho, S.J. Song, *Animal and Plant Quarantine Agency, Republic of Korea*
- [P2.06] **Phylogenetic analysis of isolated H1N1 and H1N2 swine influenza A viruses in Korea in 2016-2017**
I.O. Ouh*, S.Y. Park, J.Y. Lee, I.S. Cho, J.Y. Song, *Animal and Plant Quarantine Agency, Republic of Korea*
- [P2.07] **A serological survey of swine influenza A viruses in pigs in 2016-2017, Korea**
I.O. Ouh*, S.Y. Park, S.D. Cho, I.S. Cho, J.Y. Song, *Animal and Plant Quarantine Agency, Republic of Korea*
- [P2.09] **A novel HBV therapeutic vaccination breaks the immune tolerance and cause rapid clearance of HBs antigen and DNA in mice**
W. Tan^{*1}, X. Chual^{1,2}, Y. Deng¹, W. Wang¹, ¹MOH Key Lab Chinese Center for Disease Control and Prevention, China, ²Hebei Medical University, China
- [P2.10] **Development of a mucosal vaccine against HIV based on genetically-engineered *Saccharomyces cerevisiae* probiotic strains**
M.L. Palma³, F.S. Martins², B. Douradinha^{*1}, ¹Fondazione Ri.MED, Italy, ²UFMG, Brazil, ³University of Pittsburgh, USA

- [P2.11] **Simultaneous enhancement of cellular and humoral immunity by aluminum oxyhydroxide/graphene oxide nanocomplexes as vaccine**
X.L. Wang, F.Q. Cao, G.L. Ma*, *Peking Union Medical College & Chinese Academy of Medical Sciences, China*
- [P2.12] **Immunization with skp delivered on outer membrane vesicles protects mice against enterotoxigenic *escherichia coli* challenge**
M.P. Hays¹, D. Houben², Y. Yang¹, J. Luirink^{2,3}, P.R. Hardwidge^{*1}, ¹*Kansas State University, USA*, ²*VU University, The Netherlands*, ³*Abera Bioscience AB, Sweden*
- [P2.13] **Development and characterization of a novel chimeric virus-like particle vaccine candidate for Middle-East respiratory syndrome coronavirus**
J.M. Lan, B.Y. Huang, Y. Deng, W.L. Wang, W.J. Tan*, *MOH Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China*
- [P2.14] **A novel phosphodiester backbone oligodeoxynucleotide promotes vaccine ability to tuberculosis and flu**
J. Maeyama^{*1}, H. Asanuma¹, D. Hayashi², F. Suzuki³, Y. Ozeki⁴, S. Matsumoto⁴, S. Iho^{3,4}, S. Yamamoto², ¹*National Institute of Infectious Diseases, Japan*, ²*Japan BCG Laboratory, Japan*, ³*University of Fukui, Japan*, ⁴*Niigata University, Japan*
- [P2.15] **Immunogenic potential of different variants of HIV-1 gp140 sosip**
P. Kosztyu^{*1}, L. Barkoczi¹, L. Czernekova¹, J. Masek², R. Lukac², J. Turanek², M. Raska¹, ¹*Palacky University, Czech Republic*, ²*Veterinary Research Institute, Czech Republic*
- [P2.16] **Characterization of *Porphyromonas gingivalis* outer membrane vesicles purified by density gradient centrifugation**
R. Nakao*, S. Hirayama, M. Ohnishi, H. Senpuku, *National Institute of Infectious Diseases, Japan*
- [P2.17] **Glycine strongly enhances immunoactive membrane vesicle production from flagella-deficient *E. coli***
S. Hirayama^{*1,2}, R. Nakao¹, ¹*National Institute of Infectious Diseases, Japan*, ²*Japan Agency for Medical Research and Development, Japan*
- [P2.18] **Long-term stable silicon oil-based emulsions as novel class of adjuvants**
A. Razim^{*1}, S. Górska¹, M. Olszewski², A. Gamian¹, A. Myc¹, ¹*Polish Academy of Sciences, Poland*, ²*University of Michigan Health System, USA*
- [P2.19] **Novel nanoparticulated conjugates comprising T-cell epitopes in branched chain arrangement on lipo-Tuftsia platform**
K. Horvati^{*1,2}, G. Gyulai¹, E. Kiss¹, B. Palyi³, K. Fodor⁴, V. Farkas², N. Hegedus⁵, K. Szigeti⁵, D. Mathe⁵, S.E. Bosze², ¹*Eötvös Loránd University, Hungary*, ²*Hungarian Academy of Sciences, Hungary*, ³*National Public Health Institute, Hungary*, ⁴*University of Veterinary Medicine, Hungary*, ⁵*Semmelweis University, Hungary*
- [P2.20] **The mechanism of immune stimulation by Orf virus - a novel viral vector for therapeutic vaccinations**
M. Mueller*, A. Reguzova, H-G. Rammensee, R. Amann, *University of Tuebingen, Germany*
- [P2.21] **High frequency ultrasound to develop a platform of medical devices for intradermal injections in children**
T. Van Mulder^{*1,2}, D. Van Nuffel², M. Demolder², G. De Meyer², S. Moens³, K. Beyers^{1,3}, P. Van Damme², H. Theeten², V. Vankerckhoven¹, ¹*Novosanis nv, Belgium*, ²*University of Antwerp, Belgium*, ³*Voxdale bvba, Belgium*
- [P2.22] **Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against tuberculosis in BCG-primed mouse model**
Y-R. Lee*, H-S. Jeong, H. Lee, E. Shin, J. Yun, A-R. Kim, S-W. Lee, G.T. Chung, J.S. Yoo, *Korea National Institute of Health, Republic of Korea*
- [P2.23] **Production of oil in water emulsion adjuvant: preparedness against pandemic influenza H7N9**
M.A. Akamatsu^{*1}, V.A. Sakihara¹, M.A.S. Takano¹, E. Adami¹, S.L.C. Rico¹, A.S. Schanoski¹, C. Miyaki¹, M. Meros¹, C. Fox², P.L. Ho¹, ¹*Instituto Butantan, Brazil*, ²*Infectious Disease Research Institute, USA*
- [P2.24] **Establishment of international standards for Vi polysaccharide from *Citrobacter freundii* and *Salmonella enterica* subspecies *enterica* serovar Typhi**
F. Gao*, C. Swann, P. Rigsby, K. Lockyer, A. Logan, S. Rijpkema, B. Bolgiano, *National Institute for Biological Standards and control, UK*
- [P2.25] **Protective efficacy of a canine brucellosis vaccine candidate based on live attenuated *Salmonella* expressing recombinant *Brucella* BSCP31, Omp3b and SOD proteins in Beagles**
W.K. Kim*, E. Ochirkhuyag, S.S. Han, D.S. Tark, J. Hur, *Chonbuk National University, Republic of Korea*
- [P2.26] **Protective efficacy of an inactivated *Brucella abortus* vaccine candidate lysed by GI24 against brucellosis in Korean black goats**
W.K. Kim, E. Ochirkhuyag, S.S. Han, D.S. Tark, J. Hur*, *Chonbuk National University, Republic of Korea*
- [P2.27] **Generation of a recombinant Newcastle disease virus expressing the S1 protein of turkey enteric coronavirus for use as a bivalent vaccine**
Y. Li^{1,2}, M. Day¹, Q. Yu^{*1}, ¹*US National Poultry Research Centre, USDA-ARS, USA*, ²*Shandong Poultry Research Institute, China*
- [P2.28] **Determination of optimal age for single vaccination of growing pigs with foot-and-mouth disease bivalent vaccine in South Korea**
D. Tark^{*1}, A. Kim², H. Kim^{2,3}, J. Kim², J. Lee², M. Kwon², S. Bae², B. Kim², Y. Ko², ¹*Chonbuk National University, Republic of Korea*, ²*Animal and Plant Quarantine Agency, Republic of Korea*, ³*Kyungpook National University, Republic of Korea*

- [P2.29] ***Brucella melitensis* Rev.1 conjunctival vaccination in Alpine ibex (*Capra ibex*). Comparison of kinetics and distribution of *B. melitensis* Rev.1 infection and antibody response with domestic goat (*Capra hircus*)**
M. Riou*¹, C. Ponsart², Y. Locatelli³, A. Fadeau⁴, I. Jacques^{1,5}, R. Simon³, L. Perrot², S. Breton¹, T. Chaumeil¹, B. Blanc³, ¹INRA Centre Val de Loire, France, ²Anses/Paris-Est University, EU/OIE/FAO & National Reference Laboratory for Animal Brucellosis, Animal Health Laboratory, France, ³Réserve Zoologique de la Haute Touche, MNHN, France, ⁴Laboratoire de Touraine, France, ⁵IUT, France
- [P2.30] **Preliminary results of the DIVA potential of the MP12-Nsm-del vaccine**
L. Salekwa*¹, J. Rowland^{2,1}, P. Infante², G. Bettinger², P. Wambura¹, D. Watts², ¹Sokoine University of Agriculture, Tanzania, ²The University of Texas El Paso, USA
- [P2.31] **Distinctive immunoreactive toxins of Clostridial strains in Colombia: an extended study on sequence diversity of Clostridium spp. toxinotypes and its impact on cattle vaccination**
S. Ayala-Montaña*^{1,2}, F. Rodriguez¹, G. Tibasosa¹, J.M. Cordovez², D. Ortiz-Ortega¹, C. Renjifo-Ibáñez^{1,2}, ¹Corpoica - Colombian Corporation for Research in Agriculture, Colombia, ²University of the Andes, Colombia
- [P2.32] **The serological responses of two commercial high potency foot-and-mouth disease vaccines in pigs of pilot field trials**
H. Jo, T. Lee, J. Choi, S. Lee, J. Kim*, B. Kim, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.33] **Infection dynamics of a serotype O 2014 south east Asia lineage foot-and-mouth disease virus in pigs using three challenge methods**
T. Lee, H. Jo, J. Choi, S. Lee, J. Kim*, B. Kim, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.34] **Generation and evaluation of *Tenacibaculum maritimum* attenuated strains as novel attenuated vaccine candidates against Tenacibaculosis in Olive Flounder**
Q. Wan*, R. Kugapreethan, J-H. Lee, Jeju National University, Republic of Korea
- [P2.35] **First identification of porcine parvovirus type 6 (PPV6) in finishing pigs in the Republic of Korea**
I. Ouh*, M. Cho, J. Lee, J. Song, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.36] **Porcine parvovirus 7 in fattening pigs in the Republic of Korea**
I. Ouh*, S. Park, M. Cho, S. Cho, I. Cho, J. Song, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.37] **PLGA encapsulated inactivated-viral vaccine: An effective immunization strategy against viral haemorrhagic septicaemia virus (VHSV) infection in olive flounder**
S. Kole*, S-J. Jung, Chonnam National University, Republic of Korea
- [P2.38] **Immuno-informatic prediction of CD8⁺ T cell epitopes of PEDV Spike protein and generation of antigens containing a string of predicted epitopes**
K. Polyiam*, M. Ruengjitchatchawalya, T. Laomettachtit, K. Poomputsa, P. Mekvichitsaeng, Y. Roshorm, King Mongkut's University of Technology Thonburi, Thailand
- [P2.39] **Evaluation of a recombinant fusion GnRH vaccine in mice**
A-M. Chang*^{1,2}, C-C. Chen^{1,3}, J-W. Lee¹, M-J. Chiang^{1,2}, G-M. Ke^{1,3}, ¹National Pingtung University of Science and Technology, Taiwan, ²Animal Biologics Pilot Production Center, Taiwan, ³Research Center for Animal Biologics, Taiwan
- [P2.40] **The protective effects of maternally derived antibodies (MDAs) with F1c-LOM-BE^{rns} vaccine against virulent classical swine fever virus challenge**
S.E. Choe*, K.S. Kim, J.H. Gim, R.M. Cha, I.S. Cho, D.J. An, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.41] **Differential diagnosis for classical swine fever antibodies evaluation after the F1c-LOM-BE^{rns} vaccine**
S.E. Choe*, S.I. Lim, K.S. Kim, I.S. Cho, D.J. An, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.42] **Identification of host cellular factors interacted with nucleoprotein of severe fever thrombocytopenia syndrome virus**
E-M. Park¹, J. Ryou¹, Y. Jee¹, S-B. Hwang², J-Y. Lee¹, S-W. Park¹, Y-E. Kim*¹, ¹Centers for Disease Control & Prevention, Republic of Korea, ²Hallym University, Republic of Korea
- [P2.43] **Interactome profile of nonstructural proteins of severe fever thrombocytopenia syndrome virus interacting with the host cellular proteins including immune response process**
J-Y. Lee*¹, E-M. Park¹, J. Ryou¹, Y. Jee¹, S-B. Hwang², S-W. Park¹, Y-E. Kim¹, ¹Centers for Disease Control & Prevention, Republic of Korea, ²Hallym University, Republic of Korea
- [P2.44] **Development of inactivated bovine ephemeral fever vaccine**
M.J. Chiang*¹, A.M. Chang¹, G.M. Ke¹, ¹Nation Pingtung University of Science & Technology, Taiwan, ²Center of Animal Biologics, Taiwan, ³Animal biologics pilot production center, Taiwan
- [P2.45] **Molecular characterization of bovine rotavirus and coronavirus from Korea, 2014-2018**
S.E. Choe*, R.M. Cha, J.H. Shin, I.S. Cho, D.J. An, Animal and Plant Quarantine Agency, Republic of Korea
- [P2.46] **Development of oral vaccine delivery system against *Streptococcus suis* infection by recombinant *Lactococcus lactis***
K. Somboonsode, J. Meerak*, Chiang Mai University, Thailand
- [P2.47] **Comparison of genetic polymorphism between clinical and vaccine strains of Varicella zoster virus**
S.C. Kim*, S.H. Yeon, H.R. Hwang, J.H. Kang, J.S. Jeon, C.H. Lee, Chungbuk National University, Republic of Korea

[P2.48] Evaluation and comparison of the potential immunogenicity of two commercial inactivated bivalent Newcastle and avian influenza vaccine in SPF chicken

M.J. Mehrabanpour*¹, D. Mehrabanpour², M. Mansourian¹, ¹*Shiraz Branch, Razi Vaccine and serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Shiraz, Iran, Iran,*
²*College of Veterinary Medicine, Islamic Azad University of Kazerum, Iran*

Note:

P2.04 has been withdrawn

P2.08 will now be presented as **O4.6** in Breakout session 4: Influenza

Correct at time of print 6 Sept 2018